November 26, 2024
-- InvestorsHub NewsWire -- BNCM has issued its Quarterly Report
for the period ending September 30, 2024.
Asset Purchase
Agreement
On July 2, 2024, Bounce Mobile Systems, Inc.
(BNCM)
signed an Asset Purchase Agreement with Delex Healthcare Group,
Inc. (DELEX), a Delaware-registered corporation that owns DLX
Holdings, Inc., a Philippine-based company. This strategic
acquisition spotlights BNCM's commitment to expanding its portfolio
and operational footprint in the healthcare sector.
Share Transfer to
DELEX
BNCM is set to
transfer a total of 1.10 billion Restricted Shares
to Delex Healthcare Group, Inc. (DELEX) as
consideration for the acquisition of the latter's assets and
revenue streams.
Consolidated Financial
Statements for the 9-Month Period
The company has released its consolidated
financial statements for the first nine months of the year,
showcasing strong results. The company recorded a
total revenue of
US$7,974,848.74 and a gross profit of
US$4,840,483.97, reflecting solid operational
performance. Total net assets
stood at an impressive
US$98,343,052.27, stressing DELEX's financial stability
and growth trajectory.
DELEX EXPANSION
PLANS
It is positioned for aggressive growth, driven
by its robust foundation and a series of calculated and strong
initiatives outlined below:
1. Amplification of
DELEX Pharmacy
DELEX is gearing up for significant expansion,
planning to grow its retail pharmacy business from three existing
stores to 60 in the coming years, with 5 to 10 new locations set to
open starting Q1 2025. This aligns with a recent study forecasting
the pharmacy market to grow at a compound annual growth rate (CAGR)
of 3.77% from 2024 to 2029, reaching an estimated market volume of
US$7.75 billion by 2029. Seizing this opportunity, DELEX launched
its first branch in Barangay Sauyo, Quezon City, in October 2021,
catering to the densely populated community during the pandemic.
Since then, it has added two more branches, strategically located
near hospitals to accommodate high-volume purchases. Moving
forward, DELEX will focus on positioning new stores close to
hospitals and exploring underserved areas nationwide to accelerate
the growth of its drugstore business.
2. DELEX Acquires JMN
Brothers Pharma
To continuously diversify and strengthen the
position of DELEX in the healthcare and wellness sectors, enhancing
its offerings and market presence, it acquired JMN Brothers Pharma
Limited, Inc. (JMN Pharma). It is a company established in 2018 and
recognized for its specialization in women's health, beauty, and
ethical hospital products.
3. DELEX Supplies
Nearly 700 Hospitals Nationwide
DELEX is broadening its distribution channels
through strategic partnerships with healthcare providers to develop
integrated healthcare solutions. Currently, DELEX supplies nearly
700 hospitals nationwide and has established a presence in over 900
Mercury Drug branches. Additionally, it serves more than 160 other
drug chains and reaches nearly 400 dispensing medical doctors and
clinics. Looking ahead, DELEX aims to collaborate with more
specialized care facilities to enhance its value proposition and
support the broader healthcare ecosystem in the
Philippines.
4. DELEX Currently
Markets Over 30 Hospital Products Approved by the Philippine
FDA
DELEX continues to build momentum in the
healthcare industry with a robust portfolio of over 30 FDA-approved
hospital products, more than 20 medical device offerings, and
increasing women's health brands, all driving significant revenue
growth. In the first quarter of 2024, the company bolstered its
pipeline with the launch of 11 new pharmaceutical products and
secured distributorship agreements with four multinational medical
device companies. These strategic initiatives position DELEX for
substantial expansion across multiple therapeutic and diagnostic
areas, emphasizing its commitment to innovation and market
leadership.
5. Strategic Alliance
with Amsino, Masimo, Verathon (USA) and StermMed
(Germany)
The company is leveraging the fast-growing
medical device market in the Philippines, projected to expand at a
compound annual growth rate (CAGR) of 8.14% from 2024 to 2029,
reaching an estimated market volume of US$1.39 billion by 2029. To
capitalize on this opportunity, DELEX has strengthened its
alliances with global medical device leaders, including Amsino,
Masimo, and Verathon from the United States, as well as SternMed
GmbH from Germany. These alliances are set to drive crucial growth
in DELEX's medical device unit, solidifying its position as a key
player in the industry.
6. The Market Reach
Multiplies Reaching more than 200,000 Healthcare Professionals
Worldwide
DELEX has successfully transitioned its
on-ground ICU Forum into a dynamic online platform, offering a free
webinar series for healthcare providers launched during the
pandemic. Since its inception, as of this writing, the platform has
engaged more than 200,000 healthcare professionals worldwide,
serving as a hub for discussions on best practices, advancements in
critical care, and innovative treatment protocols. This initiative
has also forged partnerships with over 50 hospital departments and
medical societies across the Philippines, significantly boosting
organization's visibility and influence in the healthcare
industry.
7. Accelerates ISO
9001:2015 Certification Journey
The ISO 9001:2015 is an internationally
recognized framework for quality management system (QMS). It
evaluates the ability of an organization consistently deliver
high-quality products and services while meeting both the needs of
internal and external customers. Meanwhile, many industries and
countries require ISO certification as a prerequisite for
international business. In line with this global standard, DELEX
Pharma has reinforced its dedication to quality and customer
satisfaction by successfully passing the ISO 9001:2015
re-certification audit conducted by Certification Partner Global
(CPG) last July 12, 2024. This marks the third consecutive year
DELEX has maintained its certification since initially achieving it
on July 6, 2021. CPG provides auditing, certification, and training
services, helping companies adhere with ISO standards through the
integration of project management methodologies, ensuring
streamlined processes that attain customer and regulatory
requirements while driving continuous improvement.
Commenting on this accomplishment, DELEX
Pharma's CEO and Chairman of the Board, Mr. J. de Ruyter C. Oroceo,
remarked, "Securing ISO 9001:2015 certification is a significant
milestone that has greatly elevated our business
processes."
About Bounce Mobile
Systems, Inc. (OTC: BNCM)
BNCM is an Asset Management Company that
secures its assets by investing in companies with strong growth
potentials, robust revenues, significant profits, proven track
records, and promising business models with highly experienced
management teams that will exceptionally qualify for quotation and
listing on the OTC or NASDAQ markets within the next 2 to 3 years.
The growth of these companies will directly provide more employment
opportunities to the communities, improve the country's economy,
and bring greater social change.
For more information, visit:
https://www.bncm.net/
About Delex Healthcare
Group, Inc. (DELEX)
DELEX is a Delaware-registered company, and the
holding company of DLX Holdings, Inc. (DLX). DLX is a
Philippine-based parent company that holds a 60% controlling
interest in Delex Pharma International, Inc. an ISO 9001-2015
Certified company, which also holds a controlling interest in JMN
Brother's Pharma Limited, Inc. DLX and its subsidiaries are
involved in the development and distribution of pharmaceutical and
healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
Bounce Mobile Systems (PK) (USOTC:BNCM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bounce Mobile Systems (PK) (USOTC:BNCM)
Historical Stock Chart
From Dec 2023 to Dec 2024
